Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 25:2022:4953107.
doi: 10.1155/2022/4953107. eCollection 2022.

PATZ1 Induces Apoptosis through PUMA in Glioblastoma

Xiang Tao  1 , Ge Zhang  1 , Junhui Liu  1 , Baowei Ji  1 , Haitao Xu  1 , Zhibiao Chen  1
Affiliations

PATZ1 Induces Apoptosis through PUMA in Glioblastoma

Xiang Tao et al. J Oncol. .

Abstract

Aim: This study was aimed at investigating the mechanism of PATZ1 inducing apoptosis through PUMA in glioblastoma. Overexpressed PATZ1 was transfected to explore its role in inducing apoptosis in glioblastoma cells.

Methods: The expression of protein was detected by western blotting assay. qRT-PCR assay was used to detect the expression of RNA. Confocal microscopy was used to analyze the correlation between PATZ1 and PUMA. TUNEL assay was used to detect the cell apoptosis. The ability of cell proliferation was detected by MTT assay and EDU assay. The effects of PATZ1 on cell apoptosis and tumor proliferation were observed in vivo by tumor xenograft mouse model.

Results: The results showed that low PATZ1 expression correlates with poor prognosis in glioblastoma patients. Overexpression of PATZ1 inhibits glioma cell proliferation and induces apoptosis by activating intrinsic apoptotic pathways. PATZ1 colocalizes intracellularly with PUMA inducing apoptosis through PUMA in glioblastoma.

Conclusion: PATZ1 plays a biological regulatory role in inducing apoptosis in glioblastoma, and this regulatory effect is related to PUMA, and the specific mechanism remains to be further explored.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Low PATZ1 expression is associated with poor prognosis in GBM patients. (a) Kaplan-Meier survival curve of the PATZ1 expression in TCGA database. (b) Western blot analysis of PATZ1 expression in GBM cell lines. ∗∗p < 0.01.
Figure 2
Figure 2
Overexpression of PATZ1 inhibits glioma cell proliferation in vitro. (a) qRT-PCR analysis of PATZ1 expression after PATZ1 overexpression in U343 and U118-MG cells. (b) Cell proliferation after overexpression of PATZ1 in U343 and U118-MG cells by MTT assay. (c) Cell proliferation after overexpression of PATZ1 in U343 and U118-MG cells by BrdU assay. ∗p < 0.05 and ∗∗p < 0.01.
Figure 3
Figure 3
(a and b) TUNEL staining results after PATZ1 overexpression in U343 and U118-MG cells. (c–g) qRT-PCR results of PARP1, Caspase3, Caspase9, Bax, and Bcl-2 after overexpression of PATZ1 in U343 and U118-MG cells. ∗p < 0.05 and ∗∗p < 0.01.
Figure 4
Figure 4
PATZ1-induced apoptosis requires PUMA. (a) RT-PCR results of mRNA expression of PUMA after overexpression of PATZ1 in U343 and U118-MG cells. (b) RT-PCR results of mRNA expression of PATZ1 after knockdown of PATZ1 in U343 and U118-MG cells. (c) RT-PCR results of mRNA expression of PUMA after knockdown of PATZ1 in U343 and U118-MG cells. (d) RT-PCR results of mRNA expression of PUMA after knockdown of PUMA in U343 and U118-MG cells. (e) MTT results of different treatment groups in U343 cells. (f) MTT results of different treatment groups in U118-MG cells. ∗p < 0.05 and ∗∗p < 0.01.
Figure 5
Figure 5
PUMA colocalizes with PATZ1 in U118-MG cells.
Figure 6
Figure 6
PATZ1 inhibits tumor growth and induces apoptosis in vivo. (a) Tumors in mice overexpressing PATZ1. (b) Tumor growth curve in mice overexpressing PATZ1. (c–h) Expression of PARP1, Caspase3, Caspase9, Bax, Bcl-2, and PUMA in tumor tissues of mice overexpressing PATZ1. ∗p < 0.05 and ∗∗p < 0.01.
See this image and copyright information in PMC

References

    1. Vigneswaran K., Neill S., Hadjipanayis C. G. Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med. . 2015;3(7):p. 95. doi: 10.3978/j.issn.2305-5839.2015.03.57. - DOI - PMC - PubMed
    1. Ostrom Q. T., Adel Fahmideh M., Cote D. J., et al. Risk factors for childhood and adult primary brain tumors. Neuro-Oncology . 2019;21(11):1357–1375. doi: 10.1093/neuonc/noz123. - DOI - PMC - PubMed
    1. Ostrom Q. T., Gittleman H., Liao P., et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro-Oncology . 2017;19(suppl_5):v1–v88. doi: 10.1093/neuonc/nox158. - DOI - PMC - PubMed
    1. Ostrom Q. T., Gittleman H., Stetson L., Virk S. M., Barnholtz-Sloan J. S. Epidemiology of gliomas. Cancer Treatment and Research . 2015;163:1–14. doi: 10.1007/978-3-319-12048-5_1. - DOI - PubMed
    1. Tan A. C., Ashley D. M., López G. Y., Malinzak M., Friedman H. S., Khasraw M. Management of glioblastoma: state of the art and future directions. CA: a Cancer Journal for Clinicians . 2020;70(4):299–312. doi: 10.3322/caac.21613. - DOI - PubMed

LinkOut - more resources